IL308397A - Macrocyclic glucagon-like peptide 1 receptor agonists - Google Patents
Macrocyclic glucagon-like peptide 1 receptor agonistsInfo
- Publication number
- IL308397A IL308397A IL308397A IL30839723A IL308397A IL 308397 A IL308397 A IL 308397A IL 308397 A IL308397 A IL 308397A IL 30839723 A IL30839723 A IL 30839723A IL 308397 A IL308397 A IL 308397A
- Authority
- IL
- Israel
- Prior art keywords
- macrocyclic
- glucagon
- peptide
- receptor agonists
- agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191034P | 2021-05-20 | 2021-05-20 | |
| US202163254564P | 2021-10-12 | 2021-10-12 | |
| EP21383172 | 2021-12-21 | ||
| PCT/US2022/029958 WO2022246019A1 (fr) | 2021-05-20 | 2022-05-19 | Agonistes macrocycliques du récepteur du peptide 1 de type glucagon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308397A true IL308397A (en) | 2024-01-01 |
Family
ID=82016585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308397A IL308397A (en) | 2021-05-20 | 2022-05-19 | Macrocyclic glucagon-like peptide 1 receptor agonists |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4341255A1 (fr) |
| JP (1) | JP7703691B2 (fr) |
| KR (1) | KR20230173166A (fr) |
| AU (1) | AU2022275931B2 (fr) |
| BR (1) | BR112023022851A2 (fr) |
| CA (1) | CA3218345A1 (fr) |
| IL (1) | IL308397A (fr) |
| MX (1) | MX2023013717A (fr) |
| TW (1) | TWI843104B (fr) |
| WO (1) | WO2022246019A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| EP4592285A1 (fr) | 2022-09-22 | 2025-07-30 | Shionogi & Co., Ltd. | Composé à cycle condensé ayant un effet agoniste du récepteur glp-1 |
| WO2024102625A1 (fr) * | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Agonistes de récepteur du peptide 1 de type glucagon |
| EP4568664B1 (fr) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combinaison comprenant un agoniste thr-beta et un agoniste glp-1r pour son utilisation dans le traitement de l'obésité |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025158275A1 (fr) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Polythérapie utilisant des composés antagonistes du récepteur du polypeptide insulinotrope glucose-dépendant et des composés agonistes du récepteur glp-1 |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| CN119219759B (zh) * | 2024-10-22 | 2026-03-27 | 浙江工业大学 | 一种双水相萃取耦合反相柱层析分离纯化发酵液中glp-1类似物的方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102314286B1 (ko) * | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| DK3806855T5 (da) | 2018-06-15 | 2023-05-22 | Pfizer | GLP-1-receptoragonister og anvendelser deraf |
| MA54555A (fr) | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| EP3953344A4 (fr) * | 2019-04-12 | 2023-08-09 | Qilu Regor Therapeutics Inc. | Agonistes de glp-1r et leurs utilisations |
| TWI751585B (zh) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2021018023A1 (fr) | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | Modulateur du récepteur glp-1 à petites molécules |
| EP4048664A1 (fr) * | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Composés modulateurs de glp-1r |
| WO2021096284A1 (fr) | 2019-11-15 | 2021-05-20 | 일동제약(주) | Agoniste du récepteur glp-1 et son utilisation |
| CN114761395B (zh) | 2019-12-02 | 2024-11-15 | 现代药品株式会社 | Glp-1受体激动剂 |
| ES3016132T3 (en) | 2020-01-29 | 2025-05-08 | Gilead Sciences Inc | Glp-1r modulating compounds |
| JP7836762B2 (ja) | 2020-02-13 | 2026-03-27 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| IL296336A (en) | 2020-03-18 | 2022-11-01 | Lg Chemical Ltd | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| TW202206429A (zh) | 2020-04-29 | 2022-02-16 | 美商迦舒布魯姆生物有限公司 | 雜環ｇｌｐ—１促效劑 |
| MX2022015026A (es) | 2020-06-04 | 2023-01-04 | Hangzhou Sciwind Biosciences Co Ltd | Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo. |
| CN115697338B (zh) | 2020-06-10 | 2024-08-09 | 东宝紫星(杭州)生物医药有限公司 | 甲基取代的苯并二噁唑类化合物及其应用 |
| CN113801136B (zh) | 2020-06-16 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用 |
| CN115916772B (zh) | 2020-06-19 | 2025-01-14 | 江苏恒瑞医药股份有限公司 | 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| CN113831337B (zh) | 2020-06-24 | 2023-03-24 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| WO2022031994A1 (fr) | 2020-08-06 | 2022-02-10 | Qilu Regor Therapeutics Inc. | Agonistes de glp-1r et leurs utilisations |
| JP2023537501A (ja) | 2020-08-06 | 2023-09-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| CA3192601A1 (fr) | 2020-08-21 | 2022-02-24 | Terns Pharmaceuticals, Inc. | Composes en tant qu'agonistes de glp-1r |
| EP4204415A4 (fr) | 2020-08-28 | 2025-03-26 | Gasherbrum Bio, Inc. | Agonistes hétérocycliques de glp-1 |
| CA3188891A1 (fr) | 2020-09-01 | 2022-01-13 | Fanglong Yang | Derive d'imidazole condense, son procede de preparation et son utilisation medicale |
| WO2022068772A1 (fr) | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | Dérivé de benzimidazole, son procédé de préparation et son utilisation médicale |
| WO2022078152A1 (fr) | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | Agoniste du récepteur de glp-1, la benzimidazolone et son utilisation |
| US20240083886A1 (en) | 2020-10-13 | 2024-03-14 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| EP4229050A4 (fr) | 2020-10-13 | 2024-12-11 | Gasherbrum Bio, Inc. | Agonistes hétérocycliques de glp-1 |
| CN113480534B (zh) | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
-
2022
- 2022-05-17 TW TW111118381A patent/TWI843104B/zh active
- 2022-05-19 CA CA3218345A patent/CA3218345A1/fr active Pending
- 2022-05-19 MX MX2023013717A patent/MX2023013717A/es unknown
- 2022-05-19 JP JP2023571304A patent/JP7703691B2/ja active Active
- 2022-05-19 KR KR1020237039778A patent/KR20230173166A/ko active Pending
- 2022-05-19 IL IL308397A patent/IL308397A/en unknown
- 2022-05-19 WO PCT/US2022/029958 patent/WO2022246019A1/fr not_active Ceased
- 2022-05-19 EP EP22729392.5A patent/EP4341255A1/fr active Pending
- 2022-05-19 AU AU2022275931A patent/AU2022275931B2/en active Active
- 2022-05-19 BR BR112023022851A patent/BR112023022851A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230173166A (ko) | 2023-12-26 |
| WO2022246019A1 (fr) | 2022-11-24 |
| AU2022275931A1 (en) | 2023-11-02 |
| EP4341255A1 (fr) | 2024-03-27 |
| MX2023013717A (es) | 2024-01-16 |
| AU2022275931B2 (en) | 2024-08-15 |
| JP7703691B2 (ja) | 2025-07-07 |
| TW202310838A (zh) | 2023-03-16 |
| JP2024521073A (ja) | 2024-05-28 |
| CA3218345A1 (fr) | 2022-11-24 |
| BR112023022851A2 (pt) | 2024-01-23 |
| TWI843104B (zh) | 2024-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL308397A (en) | Macrocyclic glucagon-like peptide 1 receptor agonists | |
| SI3989972T1 (sl) | Agonisti receptorja za glukagonu podobni peptid 1 | |
| SI4212527T1 (sl) | Agonistična spojina receptorja GLP-1R in njena uporaba | |
| HUE070634T2 (hu) | GLP-1 receptor agonista | |
| ZA202006115B (en) | Phenylpyrrolidinone formyl peptide 2 receptor agonists | |
| IL279300A (en) | 1-GLP agonist receptors and their use | |
| IL279224A (en) | 1-GLP agonist receptors and their use | |
| LT4192831T (lt) | Heterocikliniai glp#1 agonistai | |
| IL295281B2 (en) | Heterocyclic GLP-1 agonists | |
| PL4143183T3 (pl) | Heterocykliczni agoniści glp-1 | |
| EP4317142A4 (fr) | Agoniste du récepteur de glp-1 de type thiophène et son utilisation | |
| EP4095149A4 (fr) | Triple agoniste pour récepteur du peptide-1 type glucagon, récepteur du glucagon, et récepteur du polypeptide inhibiteur gastrique | |
| GB202011604D0 (en) | GLP-1 receptor antagonists | |
| IL318291A (en) | Glucagon-like peptide 1 receptor antibodies | |
| GB202211043D0 (en) | Peptide agonist | |
| IL299680A (en) | Pyrazolone formyl peptide 2 receptor agonists | |
| HK40124254A (en) | Glucagon-like peptide 1 receptor agonists | |
| CA3272667A1 (fr) | Agonistes du récepteur du glucagon-like peptide 1 | |
| CA3272633A1 (fr) | Agonistes de récepteur du peptide 1 de type glucagon | |
| GB202316884D0 (en) | Glucagon-like peptide 1 agonists | |
| GB202219576D0 (en) | Polypeptides | |
| IL326685A (en) | Kappa opioid receptor antagonists | |
| GB202007050D0 (en) | Peptide agonist | |
| IL319173A (en) | Mutant FGF21 polypeptides | |
| HK40086535A (en) | Glp-1 receptor antagonists |